748 related articles for article (PubMed ID: 33047335)
1. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients.
Atallah B; Sadik ZG; Salem N; El Nekidy WS; Almahmeed W; Park WM; Cherfan A; Hamed F; Mallat J
Anaesthesia; 2021 Mar; 76(3):327-335. PubMed ID: 33047335
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a patient specific, targeted-intensity pharmacologic thromboprophylaxis protocol in hospitalized patients with COVID-19.
Farrar JE; Trujillo TC; Mueller SW; Beltran L; Nguyen C; Hassell K; Kiser TH
J Thromb Thrombolysis; 2022 Feb; 53(2):446-453. PubMed ID: 34410561
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units.
Lavinio A; Ercole A; Battaglini D; Magnoni S; Badenes R; Taccone FS; Helbok R; Thomas W; Pelosi P; Robba C;
Crit Care; 2021 Apr; 25(1):155. PubMed ID: 33888132
[TBL] [Abstract][Full Text] [Related]
4. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
Jonmarker S; Hollenberg J; Dahlberg M; Stackelberg O; Litorell J; Everhov ÅH; Järnbert-Pettersson H; Söderberg M; Grip J; Schandl A; Günther M; Cronhjort M
Crit Care; 2020 Nov; 24(1):653. PubMed ID: 33225952
[TBL] [Abstract][Full Text] [Related]
5. Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study.
Muñoz-Rivas N; Abad-Motos A; Mestre-Gómez B; Sierra-Hidalgo F; Cortina-Camarero C; Lorente-Ramos RM; Torres-Rubio P; Arranz-García P; Franco-Moreno AI; Gómez-Mariscal E; Mauleón-Fernández C; Alonso-García S; Rogado J; Saez-Vaquero T; Such-Diaz A; Ryan P; Moya-Mateo E; Martín-Navarro JA; Hernández-Rivas JA; Torres-Macho J; Churruca J;
Thromb Res; 2021 Mar; 199():132-142. PubMed ID: 33503547
[TBL] [Abstract][Full Text] [Related]
6. Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis.
Santoliquido A; Porfidia A; Nesci A; De Matteis G; Marrone G; Porceddu E; Cammà G; Giarretta I; Fantoni M; Landi F; Gasbarrini A; Pola R; ; D'Alfonso ME; Lo Monaco MR
J Thromb Haemost; 2020 Sep; 18(9):2358-2363. PubMed ID: 32633068
[TBL] [Abstract][Full Text] [Related]
7. Enhanced thromboprophylaxis in critically ill patients with COVID-19 infection.
Kummer RL; Considine KA; Rankin MA; Hubbard LM; Lam TS; Thornton LT; Lindsay AR; Ahiskali AS; Leatherman JW
Thromb Update; 2021 May; 3():100048. PubMed ID: 38620639
[TBL] [Abstract][Full Text] [Related]
8. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated With Risk of Postdischarge Thrombosis in Patients With COVID-19.
Li P; Zhao W; Kaatz S; Latack K; Schultz L; Poisson L
JAMA Netw Open; 2021 Nov; 4(11):e2135397. PubMed ID: 34807256
[TBL] [Abstract][Full Text] [Related]
10. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.
Artifoni M; Danic G; Gautier G; Gicquel P; Boutoille D; Raffi F; Néel A; Lecomte R
J Thromb Thrombolysis; 2020 Jul; 50(1):211-216. PubMed ID: 32451823
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study.
Shah A; Donovan K; McHugh A; Pandey M; Aaron L; Bradbury CA; Stanworth SJ; Alikhan R; Von Kier S; Maher K; Curry N; Shapiro S; Rowland MJ; Thomas M; Mason R; Holland M; Holmes T; Ware M; Gurney S; McKechnie SR
Crit Care; 2020 Sep; 24(1):561. PubMed ID: 32948243
[TBL] [Abstract][Full Text] [Related]
12. Higher Intensity Thromboprophylaxis Regimens and Pulmonary Embolism in Critically Ill Coronavirus Disease 2019 Patients.
Taccone FS; Gevenois PA; Peluso L; Pletchette Z; Lheureux O; Brasseur A; Garufi A; Talamonti M; Motte S; Nobile L; Grimaldi D; Creteur J; Vincent JL
Crit Care Med; 2020 Nov; 48(11):e1087-e1090. PubMed ID: 32769623
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study.
Ferrandis R; Escontrela B; Ferrando C; Hernández M; Herrera J; Hidalgo F; Librero J; Llau JV; Martínez A; Pajares A; Tapia B; Arruti E; Bassas E; Blasi A; Calvo A;
Rev Esp Anestesiol Reanim (Engl Ed); 2023 Mar; 70(3):129-139. PubMed ID: 36842685
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management.
Manolis AS; Manolis TA; Manolis AA; Papatheou D; Melita H
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):12-24. PubMed ID: 32924567
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art.
Dimakakos E; Gomatou G; Catalano M; Olinic DM; Spyropoulos AC; Falanga A; Maraveyas A; Liew A; Schulman S; Belch J; Gerotziafas G; Marschang P; Cosmi B; Spaak J; Syrigos K;
Anticancer Res; 2022 Jul; 42(7):3261-3274. PubMed ID: 35790272
[TBL] [Abstract][Full Text] [Related]
16. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
[TBL] [Abstract][Full Text] [Related]
17. The Incidence of Venous Thromboembolism in Critically Ill Patients with SARS-CoV-2 Infection Compared with Critically Ill Influenza and Community-Acquired Pneumonia Patients: A Retrospective Chart Review.
Boyd S; Sheng Loh K; Lynch J; Alrashed D; Muzzammil S; Marsh H; Masoud M; Bin Ihsan S; Martin-Loeches I
Med Sci (Basel); 2022 Jun; 10(2):. PubMed ID: 35736350
[TBL] [Abstract][Full Text] [Related]
18. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.
Klok FA; Kruip MJHA; van der Meer NJM; Arbous MS; Gommers D; Kant KM; Kaptein FHJ; van Paassen J; Stals MAM; Huisman MV; Endeman H
Thromb Res; 2020 Jul; 191():148-150. PubMed ID: 32381264
[TBL] [Abstract][Full Text] [Related]
19. Pragmatic study of a thromboprophylaxis algorithm in critically ill patients with SARS-COV-2 infection.
Fattorutto M; Bouckaert Y; Brauner J; Franck S; Bouton F; Heuse D; Bouckaert C; Bruyneel A
J Thromb Thrombolysis; 2022 Jan; 53(1):58-66. PubMed ID: 34173169
[TBL] [Abstract][Full Text] [Related]
20. Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review.
Jenner WJ; Kanji R; Mirsadraee S; Gue YX; Price S; Prasad S; Gorog DA
J Thromb Thrombolysis; 2021 Apr; 51(3):595-607. PubMed ID: 33586113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
